In a collaborative study “Peptide-guided nanoparticles for glioblastoma targeting” published in Journal of Controlled Release we evaluated a novel tumor penetrating peptide that targets cell surface p32, LinTT1 (AKRGARSTA), as a GBM targeting ligand for systemically-administered nanoparticles. LinTT1-functionalization increased tumor homing of iron oxide nanoworms (NWs) across a panel of five GBM models ranging from infiltratively-disseminating to angiogenic phenotypes. LinTT1-NWs homed to CD31-positive tumor blood vessels, including to transdifferentiated endothelial cells, and showed co-localization with tumor macrophages and lymphatic vessels. LinTT1-guided proapoptotic NWs exerted strong anti-glioma activity in two models of GBM, including doubling the lifespan of the mice in an aggressive orthotopic stem cell-like GBM that recapitulates the histological hallmarks of human GBM.
Lead authors of this exciting and potentially translationally relevant study were Pille Säälik and Prakash Lingasamy (both Laboratory of Cancer Biology). This work was performed in collaboration with the Department of Neurosurgery of Tartu University Clinics, team of Dr. Dinorah Friedmann-Morvinski at Tel Aviv University, and Prof. Rolf Bjerkvig at the University of Bergen.
Link to the abstract of the paper: https://www.ncbi.nlm.nih.gov/pubmed/31255690